Humana Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
2025/07/30
Humana Inc reports results for the quarter ended June 30 - Earnings Summary
  • Humana Inc HUM.N reported quarterly adjusted earnings of $6.27​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of $6.96. The mean expectation of twenty four analysts for the quarter was for earnings of $5.92 per share. Wall Street expected results to range from $5.65 to $8.28 per share.

  • Revenue rose 10.2% to $32.39 billion from a year ago; analysts expected $31.89 billion.

  • Humana Inc's reported EPS for the quarter was $4.51​.

  • The company reported quarterly net income of $545 million.

  • Humana Inc shares had fallen by 4.9% this quarter and lost 8.3% so far this year.

FORECAST CHANGES

  • The mean earnings estimate of analysts had fallen by about 1.9% in the last three months.​

  • In the last 30 days, two analysts negatively revised earnings estimates

RECOMMENDATIONS

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 8 "strong buy" or "buy," 19 "hold" and no "sell" or "strong sell." The average consensus recommendation for the managed healthcare peer group is "buy."

  • Wall Street's median 12-month price target for Humana Inc is $284.00, about 18.1% above its last closing price of $232.62

This summary was machine generated from LSEG data July 30 at 11:00 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING

ESTIMATE

ACTUAL

BEAT, MET, MISSED

Jun. 30 2025

5.92

6.27

Beat

Mar. 31 2025

10.07

11.58

Beat

Dec. 31 2024

-2.16

-2.16

Met

Sep. 30 2024

3.40

4.16

Beat

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10